//8R Hemophilia care is delivered differently in many parts of the world. Some areas of the world cannot diagnose hemophilia, other recognize the disease but do not have treatment, while others provide comprehensive care and have a plethora of services, as well as unlimited replacement therapy. The common denominator in determining the extent of care is the availability of financial support for it. Today, even wealthy nations which have provided unlimited support for care are seriously questioning or limiting expenditures on high-cost diseases. Hemophilia, a life-long chronic disease, is one which is very costly, and which serves both as a model of chronic disease care, as well as a target for financial scrutiny. Health care providers, in concert with patients and their families, must be able to provide data to ensure continued financial underwriting.

Keywords:
Hemophilia, Economics, Immune tolerance, Factor replacement, Comprehensive care
1.
Aledort LM: Lessons from hemophilia (editorial). N Engl J Med 1982;306:607–608.
2.
Lusher JM, Shapiro SS, Palascak JE, Rao AV, Levine PH, Blatt PM and the Hemophilia Study Group: Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII. N Engl J Med 1980;303:421–425.
3.
Aledort LM, Cohen M, Hilgartner MW, Lipton R: Treatment of hemophiliacs with inhibitors: Cost and effect on blood resources; in Hoyer L (ed): Factor VIII Inhibitors. New York, Liss, 1984, pp 353–365.
4.
Lipton RA: The economics of factor VIII inhibitor treatment. Semin Hematol 1994;31(suppl 4):37–38.
5.
Mariani G, Ghirardini A, Belloco R: Immune tolerance in hemophilia – Principal Results from the International Registry: Report of the Factor VIII and IX Subcommittee. Thromb Hemost 1994;72:1:155–158.
6.
Nilsson IM, Berntorp E, Zettervall O: Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988;318:947–950.
7.
Nilsson IM, Berntorp E, Lofqvist T, Pettersson H: Twenty-five years experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992;232:25.
8.
Aledort LM, Haschemeyer RH, Pettersson H: A longitudinal study of orthopedic outcomes for severe factor VIII deficient hemophiliacs. J Intern Med 1994;236:391–399.
9.
Bohn RL, Avorn J, Glynn RJ, Choodnovskiy I, Haschemeyer R, Aledort LM: Prophylactic use of factor VIII: Are the clinical benefits worth the additional cost? Blood Abstracts 1995;86:10:611a.
10.
Schramm W: Personal communication.
11.
Björkman S: Pharmacokinetics of factor VIII and factor IX; in Prophylactic Treatment of Hemophilia A and B: Current and Future Perspectives. York, Science & Medicine, 1994, pp 45–48.
12.
Ross-Degnan D, Soumerai SB, Avorn J, Bohn RL, Bright R, Aledort LM: Hemophilia home treatment: Economic analysis and implications for health policy. Int J Technol Assess Health Care 1995;11:327–344.
13.
Liesner RJ, Vora AJ, Hann IM, Lilleymann JS: Use of central venous catheters in children with severe congenital coagulopathy. Br J Haematol 1995;91:203–207.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.